Novartis Corporation, IJN inks partnership to tackle cardiovascular disease in Malaysia
Novartis Corporation (Malaysia) Sdn Bhd (NCSB) has partnered with Institut Jantung Negara (IJN) on the first-ever scientific partnership to help patients improve disease management of atherosclerotic cardiovascular disease (ASCVD) through better care and transformative therapies.
In a first-of-its-kind partnership, the collaboration between Novartis Malaysia and IJN encompasses one of the most comprehensive collaborations featuring three key areas of focus, including research collaboration aimed at generating data on ASCVD in Malaysia and measuring the outcomes of ASCVD patients.
